A Long-Term Clinical Study of TS-071 as Combination Therapy With Glimepiride in Patients With Type 2 Diabetes Mellitus
Not Applicable
- Conditions
- Type 2 Diabetes Mellitus
- Registration Number
- JPRN-jRCT2080221468
- Lead Sponsor
- Taisho Pharmaceutical co., LTD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 225
Inclusion Criteria
Type 2 diabetes mellitus
- Has been receiving treatment with glimepiride monotherapy at a fixed dose within the limit of approved continuously for more than 8 weeks.
etc.
Exclusion Criteria
- Having non-type 2 diabetes mellitus .
- Having critical Heart Disease, other ciruculatory disease, cerebrovascular disorder, pancreatic disease and hematologic disease.
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method